Patents Assigned to Boehringer Ingelheim RCV GmbH & Co. KG
-
Publication number: 20230257792Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.Type: ApplicationFiled: September 12, 2022Publication date: August 17, 2023Applicants: BOEHRINGER INGELHEIM RCV GMBH & CO KG, LONZA LTD., VALIDOGEN GMBHInventors: Karlheinz Grillitsch, Guenther Daum, Andreas Grutsch
-
Patent number: 11479798Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.Type: GrantFiled: March 28, 2018Date of Patent: October 25, 2022Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AG, VALIDOGEN GMBH, BIOMIN HOLDING GMBH, LONZA LTD.Inventors: Karlheinz Grillitsch, Guenther Daum, Andreas Grutsch
-
Patent number: 10865416Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.Type: GrantFiled: April 16, 2015Date of Patent: December 15, 2020Assignees: Boehringer Ingelheim RCV GmbH & Co KG, Vaitdogen GmbH, Lonza Ltd.Inventors: Brigitte Gasser, Diethard Mattanovich, Markus Buchetics
-
Patent number: 10752930Abstract: A method for producing a protein of interest on a manufacturing scale is based on integration, by homologous recombination, of the DNA encoding the protein of interest into a bacterial cell's genome at a pre-selected site. The manufacturing scale production of recombinant proteins is in the fed-batch mode, semi-continuous or in a chemostat.Type: GrantFiled: May 12, 2017Date of Patent: August 25, 2020Assignees: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AGInventors: Gerald Striedner, Johann Huber, Daniela Reinisch
-
Patent number: 10661264Abstract: The present invention provides novel methods of cell disruption and release of biomolecules from a cell. The invention comprises the use of positively and/or negatively charged microparticles comprising ground resin. It is particularly useful for purification of biomolecules from cell culture.Type: GrantFiled: August 14, 2018Date of Patent: May 26, 2020Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AGInventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov
-
Patent number: 10590427Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.Type: GrantFiled: April 16, 2015Date of Patent: March 17, 2020Assignees: Boehringer Ingelheim RCV GmbH & Co KG, Lonza Ltd., Validogen GmbHInventors: Brigitte Gasser, Diethard Mattanovich, Markus Buchetics
-
Patent number: 10537887Abstract: The present invention provides a novel adsorbent composition for recovering biomolecules from a fluid. The composition comprises positively and negatively charged microparticles in the form of ground particles. The adsorbent is particularly useful for purification of biomolecules from the cell culture.Type: GrantFiled: August 25, 2014Date of Patent: January 21, 2020Assignees: BOEHRINGER INGELHEIM RCV & GMBH CO KG, SANDOZ AGInventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov, Moritz Imendoerffer
-
Patent number: 10076749Abstract: The present invention provides novel methods of cell disruption and release of biomolecules from a cell. The invention comprises the use of positively and/or negatively charged microparticles comprising ground resin. It is particularly useful for purification of biomolecules from cell culture.Type: GrantFiled: August 25, 2014Date of Patent: September 18, 2018Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AGInventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov
-
Patent number: 9969969Abstract: A process for producing plasmid DNA E. coli cells comprises a pre-culture and fed-batch process. The culture media of the batch phase and the culture medium added during the feeding phase are chemically defined. The culture medium of the feeding phase contains a growth-limiting substrate and is added, for at least a fraction of the feeding phase, at a feeding rate that follows a pre-defined exponential function, thereby controlling the specific growth rate at a pre-defined value. The process results in high yield and homogeneity of plasmid DNA.Type: GrantFiled: February 19, 2009Date of Patent: May 15, 2018Assignee: BOEHRINGER INGELHEIM RCV GMBH & CO KGInventors: Hans Huber, Gerhard Weigl, Wolfgang Buchinger
-
Patent number: 9745588Abstract: The present invention provides new transcription termination signal sequences, especially a polynucleotide comprising at least two consecutive transcription termination signals, characterized in that consecutive transcription termination signals comprise at least a first and a second transcription termination signal that are at most 1000 nucleotides apart, and at least one of the termination signal has or encodes a RNA hairpin structure.Type: GrantFiled: June 1, 2012Date of Patent: August 29, 2017Assignees: SANDOZ AG, BOEHRINGER INGELHEIM RCV GMBH & CO KGInventors: Gerald Striedner, Alexander Wittwer
-
Patent number: 9683252Abstract: A method for producing a protein of interest on a manufacturing scale is based on integration, by homologous recombination, of the DNA encoding the protein of interest into a bacterial cell genome at a pre-selected site. The manufacturing scale production of recombinant proteins is in the fed-batch mode, semi-continuous or in a chemostat.Type: GrantFiled: May 16, 2008Date of Patent: June 20, 2017Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AGInventors: Gerald Striedner, Johann Huber, Daniela Keller
-
Patent number: 9677107Abstract: Disclosed is a method for producing a recombinant protein of interest, the method being characterized in by the following steps: (a) providing a fusion protein comprising an Npro autoprotease moiety and a protein of interest moiety in inclusion bodies, (b) solubilizing the inclusion bodies, (c) allowing the fusion protein to be cleaved by the Npro autoprotease moiety under chaotropic conditions, wherein the recombinant protein of interest is cleaved from the fusion protein and wherein the recombinant protein of interest is not yet renatured or simultaneously renatured, and (d) recovering the protein of interest, optionally including a renaturing step for the protein of interest.Type: GrantFiled: December 19, 2013Date of Patent: June 13, 2017Assignees: SANDOZ AG, BOEHRINGER INGELHEIM RCV GMBH & CO KGInventors: Maria Reitmeir, Rainer Schneider, Bernhard Auer
-
Patent number: 9297014Abstract: A host-vector system that uses the RNA-based copy number control mechanism of ColE1-type plasmids for regulating the expression of a marker gene allows for antibiotic-free selection of plasmids and is useful for production of plasmid DNA and recombinant proteins.Type: GrantFiled: October 28, 2008Date of Patent: March 29, 2016Assignee: BOEHRINGER INGELHEIM RCV GMBH & CO KGInventors: Reingard Grabherr, Irene Pfaffenzeller
-
Publication number: 20140170702Abstract: Disclosed is a method for producing a recombinant protein of interest, the method being characterised in by the following steps: (a) providing a fusion protein comprising an Npro autoprotease moiety and a protein of interest moiety in inclusion bodies, (b) solubilising the inclusion bodies, (c) allowing the fusion protein to be cleaved by the Npro autoprotease moiety under chaotropic conditions, wherein the recombinant protein of interest is cleaved from the fusion protein and wherein the recombinant protein of interest is not yet renatured or simultaneously renatured, and (d) recovering the protein of interest, optionally including a renaturing step for the protein of interest.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Applicants: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AGInventors: Maria REITMEIR, Rainer SCHNEIDER, Bernhard AUER
-
Publication number: 20140170701Abstract: Disclosed is a method for producing a recombinant protein of interest which is characterised by the following steps: (a) providing a first part of an Npro autoprotease and providing a second part of an Npro autoprotease, wherein said second part is fused by a peptidic bond to a protein of interest but said second part alone does not exhibit a proteolytic activity, and wherein complementation of said first part with the second part forms an autoproteolytically active Npro autoprotease, (b) contacting the first part of the Npro autoprotease with the second part of the Npro autoprotease so that an autoproteolytically active Npro autoprotease is formed and the protein of interest fused by the peptidic bond to the second part of the Npro autoprotease is proteolytically cleaved off the second part of the Npro autoprotease at the peptidic bond, and (c) recovering the protein of interest.Type: ApplicationFiled: December 19, 2013Publication date: June 19, 2014Applicants: Boehringer Ingelheim RCV GmbH & Co KG, Sandoz AGInventors: Michael SPONRING, Rainer SCHNEIDER, Bernhard AUER
-
Publication number: 20140154747Abstract: A scalable process and device for producing a bio molecule, in particular pharmaceutical grade plasmid DNA is described. The process includes the steps of alkaline lysis, neutralization and clarification and can be further extended. For separating the lysate and the precipitate an improved floatation method is disclosed. This method is based on attachment of CO2 bubbles on the precipitate floe. The CO2 is released from a carbonate salt during or after neutralization (acidification). The method of the invention is preferably carried out in an automated continuous mode applying devices for lysis and neutralization and a novel device for completely continuous clarification (separation of flocs and clarified lysate).Type: ApplicationFiled: February 5, 2014Publication date: June 5, 2014Applicant: Boehringer Ingelheim RCV GmbH & Co. KGInventors: Jochen URTHALER, Christine ASCHER, Daniel BUCHELI
-
Patent number: 8501402Abstract: A scalable process and device for producing a biomolecule, in particular pharmaceutical grade plasmid DNA. The process includes the steps of alkaline lysis and a neutralization. For separating the lysate and the precipitate, the mixture is allowed to gently flow downward through a clarification reactor that is partially filled, in its lower part, with retention material like glass beads, whereby the precipitate is retained on top of and within the retention. In a preferred embodiment of the lysis step, cell suspension and alkaline lysis solution flow through a lysis reactor that is filled with particulate material like glass beads. The process can be run continuously and fully automated.Type: GrantFiled: March 23, 2004Date of Patent: August 6, 2013Assignee: Boehringer Ingelheim RCV GmbH & Co KGInventors: Jochen Urthaler, Roman Necina, Christine Ascher, Helga Woehrer
-
Publication number: 20130059344Abstract: The present invention provides new transcription termination signal sequences, especially a polynucleotide comprising at least two consecutive transcription termination signals, characterized in that said consecutive transcription termination signals comprise at least a first and a second transcription termination signal that are at most 1000 nucleotides apart, and at least one of the termination signal has or encodes a RNA hairpin structure.Type: ApplicationFiled: June 1, 2012Publication date: March 7, 2013Applicants: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AGInventors: Gerald Striedner, Alexander Wittwer
-
Patent number: 8372959Abstract: Disclosed is a method for the production of a heterologous polypeptide of interest with a homogenous N-terminus, using a fusion polypeptide comprising the polypeptide of interest and N-terminally thereto a polypeptide exhibiting autoproteolytic function, said method comprises the steps of a) binding of the fusion polypeptide in a soluble, autoproteolytically inactive form by an affinity chromatography system, b) refolding of the fusion polypeptide, thereby activating the autoproteolytic function of the fusion polypeptide and causing cleavage of the heterologous polypeptide of interest, and c) subsequently eluting the heterologous polypeptide of interest, wherein the steps are conducted on one affinity chromatography system.Type: GrantFiled: January 11, 2012Date of Patent: February 12, 2013Assignees: Sandoz AG, Boehringer Ingelheim RCV GmbH & Co KGInventors: Alois Jungbauer, Rainer Hahn, Anne Tscheliessnig, Waltraud Kaar
-
Publication number: 20120107869Abstract: Disclosed is a method for the production of a heterologous polypeptide of interest with a homogenous N-terminus, using a fusion polypeptide comprising the polypeptide of interest and N-terminally thereto a polypeptide exhibiting autoproteolytic function, said method comprising the steps of a) binding of the fusion polypeptide in a soluble, autoproteolytically inactive form by an affinity chromatography system, b) refolding of the fusion polypeptide, thereby activating the autoproteolytic function of the fusion polypeptide and causing cleavage of the heterologous polypeptide of interest, and c) subsequently eluting the heterologous polypeptide of interest, wherein said steps are conducted on one affinity chromatography system.Type: ApplicationFiled: January 11, 2012Publication date: May 3, 2012Applicants: BOEHRINGER INGELHEIM RCV GmbH & Co KG, SANDOZ AGInventors: Alois JUNGBAUER, Rainer Hahn, Anne Tscheliessnig, Waltraud Karr